Quick Answer
Can-Fite BioPharma Ltd. reported R&D Expense of $6.69 million for fiscal year 2025.
Can-Fite BioPharma Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.69M | +16.3% |
| 2024 | $5.76M | -3.8% |
| 2023 | $5.98M | -22.9% |
| 2022 | $7.76M | -21.2% |
| 2021 | $9.85M | -17.6% |
| 2020 | $11.95M | +8.9% |
| 2019 | $10.98M | +80.7% |
| 2018 | $6.08M | — |
- Can-Fite BioPharma Ltd. showed an increase of +16.3% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Can-Fite BioPharma Ltd.’s r&d expense has grown by 10.2% (from $6.08 million to $6.69 million).
- The most recent figure is from Can-Fite BioPharma Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: